Exchange: NASDAQ·Updated 07:34 PM EDT
Upcoming Earnings: Q2 '26

Reports: Aug 10Pre-Market

Estimated EPS

-$0.78

Estimated Rev

$0M

$BLTE Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.68 down -51.11% YoY • Belite Bio anticipates completing its rolling NDA submission for tinlarebant in STGD1 to the FDA in the second quarter of 2026, an important regulatory milestone for the company.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q2 '26
-$0.78
--
--
N/A
Q1 '26
-$0.63
-$0.34
46.45%
BEAT
Q4 '25
-$0.55
-$0.38
30.43%
BEAT
Q3 '25
-$0.49
-$0.65
-33.33%
MISSED
Q2 '25
-$0.41
-$0.50
-21.95%
MISSED

Advertisement|Remove ads.